Abstract
Purpose To develop a dentate nucleus (DN) segmentation tool using deep learning (DL) applied to brain quantitative susceptibility mapping (QSM) images.
Materials and Methods Brain QSM images from 132 healthy controls and 170 individuals with cerebellar ataxia or multiple sclerosis were collected from nine different datasets worldwide for this retrospective study. Manual delineation of the DN (gray matter and white matter hilus) was first undertaken by experienced raters with a robust quality control process. Performance of automated segmentation was compared following training using several DL architectures. A two-step approach was implemented, composed of a localization model followed by DN segmentation.
Results The manual tracing protocol produced ground-truth data with high intra-rater (average ICC 0.906) and inter-rater reliability (average ICC 0.776). Initial DL architecture exploration indicated that the nnU-Net framework performed best. The two-step localization plus segmentation pipeline achieved a Dice score of 0.898±0.031 and 0.894±0.036 for left and right DN, respectively. In external validation, our algorithm outperformed the leading existing automated tool (left/right DN Dice 0.863±0.038/0.843±0.066 vs. 0.568±0.222/0.582±0.239). The model demonstrated generalizability across unseen datasets during the training step. The measures showed a superior correlation index with manual annotations and performed well in both isotropic and anisotropic QSM datasets.
Conclusion We provide a model that accurately and efficiently segments the DN from brain QSM images. The model can be readily deployed for use in observational, natural history, and treatment trials for biomarker discovery.
Competing Interest Statement
TJRR is employed by Biogen, receives a salary, and is a grant recipient from Friedreich's Ataxia Research Alliance (FARA). DHS is an Itaú Unibanco SA employee and a grant recipient from Friedreich's Ataxia Research Alliance (FARA). SC received fees from Amicus for the advisory board. LAC is funded by Friedreich's Ataxia Research Alliance (FARA) and is a consultant for Biogen Pharmaceuticals. ID is funded by Friedreich's Ataxia Research Alliance (FARA). NGK is funded by Friedreich's Ataxia Research Alliance (FARA) and CHDI Foundation Inc (New York, USA). PGH is a grant recipient from Friedreich's Ataxia Research Alliance (FARA) and the National Institute of Health (NIH) P41EB027061, P30NS076408, S10OD017974. JMJ is funded by Friedreich's Ataxia Research Alliance (FARA) and National Institute of Health (NIH). CLK reports grant FWF P35887. CL received research grants from Minoryx Therapeutics, research support from Biogen Inc and is funded by Friedreich's Ataxia Research Alliance (FARA) and NIH P41 EB027061. JL is funded by Friedreich's Ataxia Research Alliance (FARA). TM reports funding from National Institute of Health (NIH) U01 NS104326. SM is funded by the Italian MUR for the project “SEE LIFE - StrEngthEning the Italian InFrastructure of Euro-bioimaging.” AN is funded by the Italian Ministry of Health (RRC). KR is funded by Friedreich's Ataxia Research Alliance (FARA). SHS is industry support research for Reata, Biogen, Biohaven, Avidity Biosciences, Fulcrum therapeutics, Vertex, Arthex, PTC, Reneo, Larimar, has a consulting work for Reata, Biogen, Fulcrum, participated in speaking engagements for Biogen, MDA, Bionews, Medscape, and is funded by NIH, FDA, Muscular Dystrophy Association, Wyck Foundation, Friedreich's Ataxia Research Alliance, and National Ataxia Foundation. DT reports grants DFG, DE 2516/1-1 and TI 239/17-1. MCFJ reports funding from FAPESP (São Paulo Research Foundation). IHH reports Friedreich's Ataxia Research Alliance general research grant and NHMRC Ideas and Investigator Grants (2026191, 1184403). All other authors declare no financial or non-financial competing interests.
Funding Statement
This work was supported by the Friedreich's Ataxia Research Alliance (FARA General Research Grant) and grants from the Australian National Health and Medical Research Council (NHMRC Ideas Grant 1184403). The funding agencies did not influence the study design, data collection, or manuscript drafting.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee or institutional review board (IRB) respective to each project data source or site approved the use or ethics waiver for this retrospective study, and all participants provided written informed consent prior to original data collection. The TRACK-FA steering committee approved the data use, and IRB reference numbers were previously published (Monash Health Human Research Ethics Committee: RES-20-0000-139A; Children's Hospital of Philadelphia: IRB 20-017611; University of Minnesota: IRB STUDY00009047; University of Florida: IRB202000399; RWTH Aachen University: EK195/20; University of Campinas (CAAE NO): 83241318.3.1001.5404; McGill IRB Approved Project Number: 2022-8676). Ethics approval was obtained independently for the remaining studies, respectively: Ethical Committee "Carlo Romano" of the University of Naples "Federico II" (Naples A: 209/13, Naples B: 47/15), Monash University Human Research Ethics Committee (IMAGE-FRDA: 13201B, INFLAM-FRDA: 7810), and University of Minnesota IRB (1210M22281). The institutional ethics committee respective to each project approved their study (Fondazione IRCCS Istituto Neurologico "Carlo Besta": 42/2017 07/06/2017; Medical University of Graz local ethics-committee: 31-432ex18/191264-2019).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Data Availability
The patient MRI data is not publicly available due to privacy regulations. Access can be provided upon reasonable request to scientists in accordance with our Data Use and Access Policy.
